Replies to post #13723 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I do not recall any PR on the [CD137] grant extension.<

There wasn’t one and the omission was presumably intentional.

On the 4Q07 CC in early 2008, GTC guided investors to expect a meeting with the FDA in mid 2008 on the design of a clinical program for the CD137 compound. But now it appears that there is more preclinical work to be done before GTC is ready for such a meeting.